BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 38488807)

  • 1. Developing Novel Genomic Risk Stratification Models in Soft Tissue and Uterine Leiomyosarcoma.
    Dermawan JK; Chiang S; Singer S; Jadeja B; Hensley ML; Tap WD; Movva S; Maki RG; Antonescu CR
    Clin Cancer Res; 2024 May; 30(10):2260-2271. PubMed ID: 38488807
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The influence of primary site on outcomes in leiomyosarcoma: a review of clinicopathologic differences between uterine and extrauterine disease.
    Farid M; Ong WS; Tan MH; Foo LS; Lim YK; Chia WK; Soh LT; Poon D; Lee MJ; Ho ZC; Jeevan R; Chin F; Teo M; Quek R
    Am J Clin Oncol; 2013 Aug; 36(4):368-74. PubMed ID: 22772425
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Integrated genomic and transcriptomic analysis revealed mutation patterns of de-differentiated liposarcoma and leiomyosarcoma.
    Liu W; Tong H; Zhang C; Zhuang R; Guo H; Lv C; Yang H; Lin Q; Guo X; Wang Z; Wang Y; Shen F; Wang S; Dai C; Wang G; Liu J; Lu W; Zhang Y; Zhou Y
    BMC Cancer; 2020 Oct; 20(1):1035. PubMed ID: 33115433
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Integrated genome analysis of uterine leiomyosarcoma to identify novel driver genes and targetable pathways.
    Cuppens T; Moisse M; Depreeuw J; Annibali D; Colas E; Gil-Moreno A; Huvila J; Carpén O; Zikán M; Matias-Guiu X; Moerman P; Croce S; Lambrechts D; Amant F
    Int J Cancer; 2018 Mar; 142(6):1230-1243. PubMed ID: 29063609
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical Benefit in Response to Palbociclib Treatment in Refractory Uterine Leiomyosarcomas with a Common
    Elvin JA; Gay LM; Ort R; Shuluk J; Long J; Shelley L; Lee R; Chalmers ZR; Frampton GM; Ali SM; Schrock AB; Miller VA; Stephens PJ; Ross JS; Frank R
    Oncologist; 2017 Apr; 22(4):416-421. PubMed ID: 28283584
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Exome Sequencing of Uterine Leiomyosarcomas Identifies Frequent Mutations in TP53, ATRX, and MED12.
    Mäkinen N; Aavikko M; Heikkinen T; Taipale M; Taipale J; Koivisto-Korander R; Bützow R; Vahteristo P
    PLoS Genet; 2016 Feb; 12(2):e1005850. PubMed ID: 26891131
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Elimusertib (BAY1895344), a novel ATR inhibitor, demonstrates in vivo activity in ATRX mutated models of uterine leiomyosarcoma.
    Harold J; Bellone S; Manavella DD; Mutlu L; McNamara B; Hartwich TMP; Zipponi M; Yang-Hartwich Y; Demirkiran C; Verzosa MS; Choi J; Dong W; Buza N; Hui P; Altwerger G; Huang GS; Andikyan V; Clark M; Ratner E; Azodi M; Schwartz PE; Santin AD
    Gynecol Oncol; 2023 Jan; 168():157-165. PubMed ID: 36442427
    [TBL] [Abstract][Full Text] [Related]  

  • 8.
    Seligson ND; Kautto EA; Passen EN; Stets C; Toland AE; Millis SZ; Meyer CF; Hays JL; Chen JL
    Oncologist; 2019 Jul; 24(7):973-979. PubMed ID: 30541756
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Epigenetic signatures differentiate uterine and soft tissue leiomyosarcoma.
    Hasan NM; Sharma A; Ruzgar NM; Deshpande H; Olino K; Khan S; Ahuja N
    Oncotarget; 2021 Aug; 12(16):1566-1579. PubMed ID: 34381562
    [TBL] [Abstract][Full Text] [Related]  

  • 10. HPV51-associated Leiomyosarcoma: A Novel Class of TP53/RB1-Wildtype Tumor With Predilection for the Female Lower Reproductive Tract.
    Williams EA; Montesion M; Lincoln V; Tse JY; Hiemenz MC; Mata DA; Shah BB; Shoroye A; Alexander BM; Werth AJ; Foley-Peres K; Milante RR; Ross JS; Ramkissoon SH; Williams KJ; Adhikari LJ; Zuna RE; LeBoit PE; Lin DI; Elvin JA
    Am J Surg Pathol; 2022 Jun; 46(6):729-741. PubMed ID: 35034043
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Integrated histologic and molecular analysis of uterine leiomyosarcoma and 2 benign variants with nuclear atypia.
    Gao T; Finkelman BS; Ban Y; Li Y; Yin P; Bulun SE; Lu X; Ha C; Wei JJ
    Cancer Sci; 2021 May; 112(5):2046-2059. PubMed ID: 33338329
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Molecular biomarkers for uterine leiomyosarcoma and endometrial stromal sarcoma.
    Tsuyoshi H; Yoshida Y
    Cancer Sci; 2018 Jun; 109(6):1743-1752. PubMed ID: 29660202
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Genomic Database Analysis of Uterine Leiomyosarcoma Mutational Profile.
    Astolfi A; Nannini M; Indio V; Schipani A; Rizzo A; Perrone AM; De Iaco P; Pirini MG; De Leo A; Urbini M; Secchiero P; Pantaleo MA
    Cancers (Basel); 2020 Jul; 12(8):. PubMed ID: 32751892
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Relationships between highly recurrent tumor suppressor alterations in 489 leiomyosarcomas.
    Schaefer IM; Lundberg MZ; Demicco EG; Przybyl J; Matusiak M; Chibon F; Ingram DR; Hornick JL; Wang WL; Bauer S; Baker LH; Lazar AJ; van de Rijn M; Mariño-Enríquez A; Fletcher JA
    Cancer; 2021 Aug; 127(15):2666-2673. PubMed ID: 33788262
    [TBL] [Abstract][Full Text] [Related]  

  • 15. External validation of a prognostic nomogram for overall survival in women with uterine leiomyosarcoma.
    Iasonos A; Keung EZ; Zivanovic O; Mancari R; Peiretti M; Nucci M; George S; Colombo N; Carinelli S; Hensley ML; Raut CP
    Cancer; 2013 May; 119(10):1816-22. PubMed ID: 23456762
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Genomic Landscape of Uterine Sarcomas Defined Through Prospective Clinical Sequencing.
    Hensley ML; Chavan SS; Solit DB; Murali R; Soslow R; Chiang S; Jungbluth AA; Bandlamudi C; Srinivasan P; Tap WD; Rosenbaum E; Taylor BS; Donoghue MTA; Hyman DM
    Clin Cancer Res; 2020 Jul; 26(14):3881-3888. PubMed ID: 32299819
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Molecular-Based Immunohistochemical Algorithm for Uterine Leiomyosarcoma Diagnosis.
    Momeni-Boroujeni A; Yousefi E; Balakrishnan R; Riviere S; Kertowidjojo E; Hensley ML; Ladanyi M; Ellenson LH; Chiang S
    Mod Pathol; 2023 Apr; 36(4):100084. PubMed ID: 36788080
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Identification of a Novel MAN1A1-ROS1 Fusion Gene Through mRNA-based Screening for Tyrosine Kinase Gene Aberrations in a Patient with Leiomyosarcoma.
    Suehara Y; Kohsaka S; Hayashi T; Akaike K; Kurisaki-Arakawa A; Sato S; Kobayashi E; Mizuno S; Ueno T; Morii T; Okuma T; Kurihara T; Hasegawa N; Sano K; Sasa K; Okubo T; Kim Y; Mano H; Saito T
    Clin Orthop Relat Res; 2021 Apr; 479(4):838-852. PubMed ID: 33196586
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Nanocind Signature Is an Independent Prognosticator of Recurrence and Death in Uterine Leiomyosarcomas.
    Croce S; Lesluyes T; Valle C; M'Hamdi L; Thébault N; Pérot G; Stoeckle E; Noël JC; Fontanges Q; Devouassoux-Shisheboran M; Querleu D; Guyon F; Floquet A; Chakiba C; Mayeur L; Rebier F; MacGrogan GM; Soubeyran I; Le Guellec S; Chibon F
    Clin Cancer Res; 2020 Feb; 26(4):855-861. PubMed ID: 31796515
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    Williams EA; Sharaf R; Decker B; Werth AJ; Toma H; Montesion M; Sokol ES; Pavlick DC; Shah N; Williams KJ; Venstrom JM; Alexander BM; Ross JS; Albacker LA; Lin DI; Ramkissoon SH; Elvin JA
    JCO Precis Oncol; 2020; 4():. PubMed ID: 33015533
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.